Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.050 AlteredExpression disease BEFREE The overexpression of MEK5 in APO- MCF-7 breast carcinoma cells shows that this MAPK signaling protein represents a potent survival molecule. 12219026 2002
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.070 Biomarker phenotype BEFREE Taken together, our results establish MEK5 as a key signalling molecule associated with prostate carcinogenesis. 12618764 2003
CUI: C1269955
Disease: Tumor Cell Invasion
Tumor Cell Invasion 		0.050 Biomarker phenotype BEFREE MEK5 transfection experiments confirm its ability to induce proliferation (P < 0.0001), motility (P = 0.0001) and invasion in prostate cancer cells (P = 0.0001). 12618764 2003
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.040 AlteredExpression disease BEFREE We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. 12618764 2003
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 AlteredExpression disease BEFREE We demonstrated that MEK5 expression is increased in prostate cancer as compared to benign prostatic tissue. 12618764 2003
CUI: C0033578
Disease: Prostatic Neoplasms
Prostatic Neoplasms 		0.010 AlteredExpression group LHGDN MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. 12618764 2003
CUI: C0153690
Disease: Secondary malignant neoplasm of bone
Secondary malignant neoplasm of bone 		0.010 AlteredExpression disease BEFREE Strong MEK5 expression correlates with the presence of bony metastases and less favourable disease-specific survival. 12618764 2003
CUI: C0936223
Disease: Metastatic Prostate Carcinoma
Metastatic Prostate Carcinoma 		0.010 AlteredExpression disease BEFREE MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. 12618764 2003
CUI: C1282496
Disease: Metastasis from malignant tumor of prostate
Metastasis from malignant tumor of prostate 		0.010 AlteredExpression disease BEFREE MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion. 12618764 2003
CUI: C0596263
Disease: Carcinogenesis
Carcinogenesis 		0.070 Biomarker phenotype BEFREE MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies. 15378007 2004
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.050 AlteredExpression disease BEFREE Compared with nonmalignant breast epithelial cells or normal tissues without constitutively active Stat3 signaling, MEK5 protein levels are remarkably higher in breast carcinoma cell lines and cancer tissues with constitutively activated Stat3. 15378007 2004
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.040 AlteredExpression disease BEFREE We also investigated MEK5 expression in different breast carcinoma cell lines and breast cancer tissues using tissue array analysis. 15378007 2004
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 Biomarker group BEFREE MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies. 15378007 2004
CUI: C0205699
Disease: Carcinomatosis
Carcinomatosis 		0.010 AlteredExpression phenotype BEFREE MEK5 may be one of the Stat3-regulated genes and plays its essential roles in oncogenesis mediated by aberrantly activated Stat3 signaling in breast carcinomatosis and malignancies. 15378007 2004
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.040 Biomarker disease BEFREE Recently, MEK5 has been shown to overexpress in prostate cancer and is associated with poor survival outcome. 15805119 2005
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 Biomarker disease BEFREE Recently, MEK5 has been shown to overexpress in prostate cancer and is associated with poor survival outcome. 15805119 2005
CUI: C1654637
Disease: androgen independent prostate cancer
androgen independent prostate cancer 		0.010 AlteredExpression disease BEFREE Therefore, we examined the endogenous expression status of MEK5 in androgen-independent prostate cancer cells upon recombinant adenovirus-mediated introduction of MBP-1. 15805119 2005
CUI: C0025149
Disease: Medulloblastoma
Medulloblastoma 		0.010 AlteredExpression disease BEFREE Only those cells expressing MAP/ERK kinase 5 (MEK5) plus ERK5 or MEF2 constructs underwent apoptosis, indicating that overexpression of either is sufficient to induce medulloblastoma cell death. 15994942 2005
CUI: C0278510
Disease: Childhood Medulloblastoma
Childhood Medulloblastoma 		0.010 AlteredExpression disease BEFREE Only those cells expressing MAP/ERK kinase 5 (MEK5) plus ERK5 or MEF2 constructs underwent apoptosis, indicating that overexpression of either is sufficient to induce medulloblastoma cell death. 15994942 2005
CUI: C0278876
Disease: Adult Medulloblastoma
Adult Medulloblastoma 		0.010 AlteredExpression disease BEFREE Only those cells expressing MAP/ERK kinase 5 (MEK5) plus ERK5 or MEF2 constructs underwent apoptosis, indicating that overexpression of either is sufficient to induce medulloblastoma cell death. 15994942 2005
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.030 GeneticVariation group BEFREE Finally, additional CIN-tumor-associated DNA amplifications were identified for EXT1 (8q24.11) and MYC (8q24.12) as well as DNA deletions for MAP2K5 (15q23) and LAMA3 (18q11.2). 17143621 2007
CUI: C0206708
Disease: Cervical Intraepithelial Neoplasia
Cervical Intraepithelial Neoplasia 		0.010 GeneticVariation disease BEFREE Finally, additional CIN-tumor-associated DNA amplifications were identified for EXT1 (8q24.11) and MYC (8q24.12) as well as DNA deletions for MAP2K5 (15q23) and LAMA3 (18q11.2). 17143621 2007
CUI: C1332922
Disease: Cervical Squamous Intraepithelial Neoplasia
Cervical Squamous Intraepithelial Neoplasia 		0.010 GeneticVariation disease BEFREE Finally, additional CIN-tumor-associated DNA amplifications were identified for EXT1 (8q24.11) and MYC (8q24.12) as well as DNA deletions for MAP2K5 (15q23) and LAMA3 (18q11.2). 17143621 2007
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.040 AlteredExpression disease BEFREE Taken together, our data show that induction of MEK5/ERK5 signalling is linked to activation of the DNA replication licensing pathway in PCa, and that the strong prognostic value of MCM proteins may result from their function as relay stations coupling growth regulatory pathways to genome duplication. 17406359 2007
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.040 AlteredExpression disease BEFREE Taken together, our data show that induction of MEK5/ERK5 signalling is linked to activation of the DNA replication licensing pathway in PCa, and that the strong prognostic value of MCM proteins may result from their function as relay stations coupling growth regulatory pathways to genome duplication. 17406359 2007